Form 4 Filing for Climb Bio, Inc.

Thomas Stephen Basil, a director at Climb Bio, Inc. (CLYM), reported the sale of 100,000 shares of common stock on September 15, 2026, pursuant to a Rule 10b5-1 trading plan. The weighted average sale price was $13.6682, with individual sales ranging from $13.3800 to $14.3400. Following this transaction, Mr. Basil owns 467,969 shares. A footnote indicates that the reported shares include 413,312 shares received through a pro-rata in-kind distribution from Sera Medicines, LLC. The filing was signed by Chandra Adams as Attorney-in-Fact.